Seminars in arthritis and rheumatism最新文献

{"title":"New anti-TNF biologics in RA: What is new and what is old?","authors":"Tsutomu Takeuchi","doi":"10.1016/j.semarthrit.2025.152693","DOIUrl":"https://doi.org/10.1016/j.semarthrit.2025.152693","url":null,"abstract":"<p><p>This review summarizes the recent advancement of fragmented immunoglobulin molecules targeting on Tumot Necrosis Factor (TNF) alpha and highlighted the nanobody, which is the first approved product for the patients with rheumatoid arthritis (RA), ozoralizumab (OZR). Background for the clinical development, pharmakokinetics, and clinical trial data for OZR were shown. It has been approved in Japan in 2022 and marked as the fixth products of TNF inhibitors for RA in Japan. The similarities and differences among these products are discussed in this review.</p>","PeriodicalId":21715,"journal":{"name":"Seminars in arthritis and rheumatism","volume":" ","pages":"152693"},"PeriodicalIF":4.6,"publicationDate":"2025-04-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143781121","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Development of a prediction model for poor prognosis in childhood-onset Takayasu's arteritis","authors":"Yingjie Xu ,&nbsp;Wenquan Niu ,&nbsp;Min Kang ,&nbsp;Jia Zhu ,&nbsp;Fan Liu ,&nbsp;Baoping He ,&nbsp;Weihong Chu ,&nbsp;Lian Wang ,&nbsp;Xue Zhao ,&nbsp;Gaixiu Su ,&nbsp;Dan Zhang ,&nbsp;Tong Yue ,&nbsp;Ming Li ,&nbsp;Jianming Lai ,&nbsp;Xiaohui Li","doi":"10.1016/j.semarthrit.2025.152711","DOIUrl":"10.1016/j.semarthrit.2025.152711","url":null,"abstract":"<div><h3>Objectives</h3><div>Childhood-onset Takayasu's arteritis (cTAK) is a rare disease with high recurrence rates, vascular complications, and mortality. This study aimed to identify the risk factors for poor prognosis in hospitalized patients with cTAK and develop a nomogram prediction model.</div></div><div><h3>Methods</h3><div>This was a prospective longitudinal multicenter cohort study. Cohorts were categorized into poor and good prognosis groups according to follow-up outcomes. Poor prognosis included vascular complications, disease recurrence, persistent non-remission, and cTAK-related death.</div></div><div><h3>Results</h3><div>Of the 111 patients, 73 (65.8%) and 38 (34.2%) were categorized into the good and poor prognosis groups, respectively, with a median follow-up of 36.0 [24.0, 60.0] months. Seven independent factors for poor prognosis of cTAK were identified: the Indian Takayasu Clinical Activity Score with the Acute-Phase Response (ITAS.A), internal carotid artery stenosis, external carotid artery stenosis, aortic insufficiency, mitral insufficiency, tricuspid insufficiency, and hypertensive heart disease (odds ratios: 1.20, 3.21, 3.57, 3.88, 9.08, 15.67, and 7.42, respectively; all <em>P</em> values &lt; 0.05). The nomogram prediction model yielded an area under the receiver operating characteristic curve of 0.79. The C-index of the nomogram constructed based on the prediction model was 0.73. The accuracy of this model was 67.0% after bootstrapping for 1000 repetitions.</div></div><div><h3>Conclusion</h3><div>We used easily accessible clinical and laboratory data to establish a nomogram model for predicting the probability of poor prognosis with hospitalized cTAK patients.</div></div>","PeriodicalId":21715,"journal":{"name":"Seminars in arthritis and rheumatism","volume":"72 ","pages":"Article 152711"},"PeriodicalIF":4.6,"publicationDate":"2025-03-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143725416","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Incidence of aortic aneurysm, dissection, or rupture among patients with polymyalgia rheumatica and giant cell arteritis","authors":"Kylie Carlson ,&nbsp;Mahmut Kaymakci ,&nbsp;Sebastian E. Sattui ,&nbsp;Michael Putman","doi":"10.1016/j.semarthrit.2025.152714","DOIUrl":"10.1016/j.semarthrit.2025.152714","url":null,"abstract":"<div><h3>Background</h3><div>Patients with polymyalgia rheumatica (PMR) may have subclinical large vessel vasculitis. We compared the incidence of aortic complications in PMR and giant cell arteritis (GCA) to the general population.</div></div><div><h3>Methods</h3><div>A retrospective cohort study was performed of patients with PMR and GCA identified by ≥2 ICD-9/ICD-10-CM diagnostic codes and concurrent corticosteroid treatment in the US-based TriNetX database (2000–2024). Matched general population controls were identified (1:3 ratio). The primary outcome, aortic complications, was a composite of aortic aneurysm and dissection/rupture. Adjusted hazard ratios (aHR) were calculated using Cox proportional cause-specific hazard models with PMR as the referent category.</div></div><div><h3>Findings</h3><div>Of 57,336 patients, 17,327 had PMR, 4,734 had GCA, and 35,275 were matched controls. Median follow-up time was 3.74 years (interquartile range, 1.8–6.4). The incidence rate of any aortic complication per 1,000 person-years was highest for GCA (11.69), followed by PMR (6.78) and the general population (5.09). Compared to patients with PMR, patients with GCA had a higher risk of any aortic complication (aHR 1.87, 95 % confidence interval (CI) 1.58–2.21); the general population risk was similar (aHR 0.95, 95 % CI 0.84–1.06). In a sensitivity analysis, patients with PMR who later developed GCA had a risk similar to those initially diagnosed with GCA (aHR 0.85, 95 % CI 0.60–1.19).</div></div><div><h3>Interpretation</h3><div>Patients with PMR had a similar risk of large vessel complications compared to the general population and a lower risk compared to those with GCA. These results do not support screening for aortic inflammation among patients with PMR who lack features of GCA.</div></div>","PeriodicalId":21715,"journal":{"name":"Seminars in arthritis and rheumatism","volume":"72 ","pages":"Article 152714"},"PeriodicalIF":4.6,"publicationDate":"2025-03-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143680101","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Polygenic risk scores for rheumatoid arthritis and idiopathic pulmonary fibrosis and associations with RA, interstitial lung abnormalities, and quantitative interstitial abnormalities among smokers","authors":"Gregory C McDermott ,&nbsp;Matthew Moll ,&nbsp;Michael H Cho ,&nbsp;Keigo Hayashi ,&nbsp;Pierre-Antoine Juge ,&nbsp;Tracy J Doyle ,&nbsp;Misti L Paudel ,&nbsp;Gregory L Kinney ,&nbsp;Vanessa L Kronzer ,&nbsp;John S Kim ,&nbsp;Lauren A O'Keeffe ,&nbsp;Natalie A Davis ,&nbsp;Elana J Bernstein ,&nbsp;Paul F Dellaripa ,&nbsp;Elizabeth A Regan ,&nbsp;Gary M Hunninghake ,&nbsp;Edwin K Silverman ,&nbsp;Samuel Y Ash ,&nbsp;Raul San Jose Estepar ,&nbsp;George R Washko ,&nbsp;Jeffrey A Sparks","doi":"10.1016/j.semarthrit.2025.152708","DOIUrl":"10.1016/j.semarthrit.2025.152708","url":null,"abstract":"<div><h3>Objective</h3><div>Genome-wide association studies (GWAS) facilitate construction of polygenic risk scores (PRSs) for rheumatoid arthritis (RA) and idiopathic pulmonary fibrosis (IPF). We investigated associations of RA and IPF PRSs with RA and high-resolution chest computed tomography (HRCT) parenchymal lung abnormalities.</div></div><div><h3>Methods</h3><div>Participants in COPDGene, a prospective multicenter cohort of current/former smokers, had chest HRCT at study enrollment. Using genome-wide genotyping, RA and IPF PRSs were constructed using GWAS summary statistics. HRCT imaging underwent visual inspection for interstitial lung abnormalities (ILA) and quantitative CT (QCT) analysis using a machine-learning algorithm that quantified percentage of normal lung, interstitial abnormalities, and emphysema. RA was identified through self-report and DMARD use. We investigated associations of RA and IPF PRSs with RA, ILA, and QCT features using multivariable logistic and linear regression.</div></div><div><h3>Results</h3><div>We analyzed 9,230 COPDGene participants (mean age 59.6 years, 46.4 % female, 67.2 % non-Hispanic White, 32.8 % Black/African American). In non-Hispanic White participants, RA PRS was associated with RA diagnosis (OR 1.32 per unit, 95 %CI 1.18–1.49) but not ILA or QCT features. Among non-Hispanic White participants, IPF PRS was associated with ILA (OR 1.88 per unit, 95 %CI 1.52–2.32) and quantitative interstitial abnormalities (adjusted β=+0.50 % per unit, <em>p</em> = 7.3 × 10⁻⁸) but not RA. There were no statistically significant associations among Black/African American participants.</div></div><div><h3>Conclusions</h3><div>RA and IPF PRSs were associated with their intended phenotypes among non-Hispanic White participants but performed poorly among Black/African American participants. PRS may have future application to risk stratify for RA diagnosis among patients with ILD or for ILD among patients with RA.</div></div>","PeriodicalId":21715,"journal":{"name":"Seminars in arthritis and rheumatism","volume":"72 ","pages":"Article 152708"},"PeriodicalIF":4.6,"publicationDate":"2025-03-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143632028","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Application of factor D and other complement factors as systemic sclerosis-associated pulmonary hypertension: Comment of the article by Petrow et al","authors":"Xian-zhe Zhou ,&nbsp;Rong-hong Guo ,&nbsp;Yan-li Yang ,&nbsp;James Cheng-Chung Wei ,&nbsp;Ke Xu ,&nbsp;Li-yun Zhang","doi":"10.1016/j.semarthrit.2025.152713","DOIUrl":"10.1016/j.semarthrit.2025.152713","url":null,"abstract":"","PeriodicalId":21715,"journal":{"name":"Seminars in arthritis and rheumatism","volume":"72 ","pages":"Article 152713"},"PeriodicalIF":4.6,"publicationDate":"2025-03-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143679244","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Real-world evidence of the antifibrotic nintedanib in rheumatoid arthritis-interstitial lung disease. National multicenter study of 74 patients","authors":"Belén Atienza-Mateo ,&nbsp;Ana Serrano-Combarro ,&nbsp;Jesús Loarce Martos ,&nbsp;Nuria Vegas-Revenga ,&nbsp;María Martín López ,&nbsp;Santos Castañeda ,&nbsp;Rafael B. Melero-González ,&nbsp;Natalia Mena Vázquez ,&nbsp;Carmen Carrasco-Cubero ,&nbsp;Carolina Díez Morrondo ,&nbsp;David Castro Corredor ,&nbsp;Tomás Ramón Vázquez Rodríguez ,&nbsp;Andrea García Valle ,&nbsp;Gema Bonilla ,&nbsp;Marina Rodríguez López ,&nbsp;Ignacio Braña Abascal ,&nbsp;Sara María Rojas Herrera ,&nbsp;Juan C Sarmiento-Monroy ,&nbsp;Pablo Andújar Brazal ,&nbsp;Diego Ferrer ,&nbsp;Christian Omar Anchorena Diaz","doi":"10.1016/j.semarthrit.2025.152710","DOIUrl":"10.1016/j.semarthrit.2025.152710","url":null,"abstract":"<div><h3>Objective</h3><div>To assess the effectiveness and safety of the antifibrotic drug nintedanib in rheumatoid arthritis (RA)-related interstitial lung disease (ILD) and a progressive phenotype in clinical practice.</div></div><div><h3>Methods</h3><div>National Spanish multicenter study of RA-ILD patients to whom nintedanib was added due to progressive fibrosing ILD. Outcome variables were effectiveness, retention rate and safety. Forced vital capacity (FVC) evolution was the primary endpoint. A comparative study between our cohort and those RA-ILD patients included in the INBUILD trial (<em>n</em> = 89, 42 treated with nintedanib) was performed.</div></div><div><h3>Results</h3><div>A total of 74 patients (31 women/43 men) were collected, mean age of 69.3 ± 8.8 years. Median [IQR] ILD duration up to antifibrotic initiation was 51 [22–77.5] months. Besides corticosteroids (<em>n</em> = 54), nintedanib was used combined with cDMARD (<em>n</em> = 21), bDMARD (<em>n</em> = 46) and/or JAKi (<em>n</em> = 4) and monotherapy (<em>n</em> = 3). Mean FVC one year before nintedanib start was 81.9 ± 21.2 (% pred.), whilst mean baseline FVC was 73.7 ± 22.5 (% pred.). After a median follow-up of 15 [10–22, 4–9] months, no significant decline in mean FVC or DLCO values was observed. Moreover, the evolution of DLCO and FVC significantly differed from a predictive model that assumed their changes without the drug. The retention rate with nintedanib was 78.4 %. During the follow up, 16.7 % of patients showed ILD progression or progressive pulmonary fibrosis. Gastrointestinal adverse events were the most common reason for nintedanib discontinuation. Compared with INBUILD trial, patients from clinical practice were older, had a higher tobacco exposure, time since ILD diagnosis was longer and treatment with combined immunosuppressants was more frequent. However, baseline mean values of FVC and DLCO were similar in both groups.</div></div><div><h3>Conclusion</h3><div>Nintedanib seems to be effective and relatively safe in progressive fibrosing RA-ILD despite clinical differences with the INBUILD trial.</div></div>","PeriodicalId":21715,"journal":{"name":"Seminars in arthritis and rheumatism","volume":"72 ","pages":"Article 152710"},"PeriodicalIF":4.6,"publicationDate":"2025-03-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143674658","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Effectiveness and safety of anti-CD20 monoclonal antibodies versus csDMARDs in anti-Jo-1 antisynthetase syndrome: A retrospective cohort study","authors":"Shuhui Sun ,&nbsp;Jiajia Jin ,&nbsp;Jie Chen ,&nbsp;Kaiwen Wang ,&nbsp;Wanlong Wu ,&nbsp;Xiaodong Wang ,&nbsp;Yanyan Song ,&nbsp;Shuang Ye","doi":"10.1016/j.semarthrit.2025.152712","DOIUrl":"10.1016/j.semarthrit.2025.152712","url":null,"abstract":"<div><h3>Objectives</h3><div>Anti-Jo-1 antisynthetase syndrome (Jo1⁺ASyS) is the most common form of idiopathic inflammatory myopathy with high relapse rates and limited treatment options beyond csDMARDs, which frequently fail to achieve adequate disease control. This study aimed to evaluate the efficacy and safety of anti-CD20 monoclonal antibodies (CD20mAbs) compared to conventional synthetic(cs) DMARDs in patients with Jo1⁺ASyS.</div></div><div><h3>Methods</h3><div>A single-center retrospective cohort of patients with Jo1⁺ASyS were collected at RenJi Hospital in China (2007–2023). A prevalent new-user design with time-based propensity scores, applied without replacement, was used to match CD20mAb and csDMARD users. The primary outcome was the percentage of patients reaching Low Disease Activity (5-item LDA), as defined by the absence of active arthritis, myositis, ILD, fever, and prednisone dosage ≤7.5 mg/day.</div></div><div><h3>Results</h3><div>A total of 166 eligible treatment regimens, including CD20mAbs and csDMARDs, were extracted from 128 Jo1⁺ASyS patients with a median follow-up period of 5 years. Utilizing propensity score, 49 pairs of individual prescriptions for CD20mAbs and csDMARDs users were matched. The group treated with CD20mAbs exhibited a significantly higher rate of achieving LDA compared to those treated with csDMARDs (46.9 % vs. 22.4 %, <em>p</em> = 0.011). No significant differences in exposure-adjusted incidence rate were detected between the two treatment modalities (CD20mAbs vs. csDMARDs = 7.911 vs. 6.479 per 100 patient-yr, RR = 1.22; 95 % CI: 0.64, 2.36), with respect to major infections. Sensitivity analyses further confirmed the robustness of the superior effectiveness of the CD20mAbs compared to the csDMARDs.</div></div><div><h3>Conclusion</h3><div>CD20mAbs exhibited remarkable treatment efficacy and acceptable safety in patients with Jo1⁺ASyS. Cumulative evidence, including ours suggested that CD20mAbs should be considered as a first-line option for Jo1⁺ASyS.</div></div>","PeriodicalId":21715,"journal":{"name":"Seminars in arthritis and rheumatism","volume":"72 ","pages":"Article 152712"},"PeriodicalIF":4.6,"publicationDate":"2025-03-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143680019","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Core domain set for chronic and/or recurrent manifestations of calcium pyrophosphate deposition disease: OMERACT delphi survey to establish consensus","authors":"Yiling Zhang ,&nbsp;Sara K. Tedeschi ,&nbsp;Abhishek Abhishek ,&nbsp;Owen Hensey ,&nbsp;David Grossberg ,&nbsp;Ken Cai ,&nbsp;Beverley Shea ,&nbsp;Jasvinder A. Singh ,&nbsp;Robin Christensen ,&nbsp;Teodora Serban ,&nbsp;Edoardo Cipolletta ,&nbsp;Konstantinos Parperis ,&nbsp;Cesar Diaz-Torne ,&nbsp;Geraldine M McCarthy ,&nbsp;Fabio Becce ,&nbsp;Tamer A Gheita ,&nbsp;Silvia Sirotti ,&nbsp;Sara Nysom Christiansen ,&nbsp;Luis Coronel ,&nbsp;Lisa K Stamp ,&nbsp;Nicola Dalbeth","doi":"10.1016/j.semarthrit.2025.152669","DOIUrl":"10.1016/j.semarthrit.2025.152669","url":null,"abstract":"<div><h3>Objective</h3><div>To agree on important domains for the Outcome Measures in Rheumatology (OMERACT) core domain set for chronic and/or recurrent manifestations of calcium pyrophosphate deposition (CPPD) disease.</div></div><div><h3>Methods</h3><div>Patient research partners (PRPs) and other participants (mainly clinicians and researchers) contributed to three rounds of a consensus survey using Delphi methodology. Consensus was defined if ≥70% of both patients and other participants scored the domain as ‘critically important domain to include’. In a subsequent ranking exercise, all participants were asked to select and rank up to 10 of the domains reaching consensus.</div></div><div><h3>Results</h3><div>Fifteen domains reached consensus as critically important. Within the Pathophysiological Manifestations area, these were joint pain, joint tenderness, joint swelling, acute CPP crystal arthritis flare, joint damage on imaging tests, joint calcification on imaging tests, and crystals in joint fluid. Within the Life Impact area, these were overall function, ability to complete daily tasks, ability to work, health related quality of life, patient global assessment response to treatment, patient global assessment of disease activity, physician global assessment of disease activity, and patient satisfaction with treatment. No domains within the Societal/Resource Use area reached consensus as critically important. In the ranking exercise, joint pain, joint tenderness, joint swelling, acute CPP crystal arthritis flare and overall function were most highly ranked.</div></div><div><h3>Conclusion</h3><div>This work has identified potential domains for the OMERACT core domain set for chronic and/or recurrent manifestations of CPPD disease. There was strong support for joint pain, joint tenderness, joint swelling, acute CPP crystal arthritis flare, overall function, and global assessments of disease activity as core domains.</div></div>","PeriodicalId":21715,"journal":{"name":"Seminars in arthritis and rheumatism","volume":"72 ","pages":"Article 152669"},"PeriodicalIF":4.6,"publicationDate":"2025-03-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143611037","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Tuft resorption in patients with psoriatic arthritis","authors":"Fadi Kharouf ,&nbsp;Shangyi Gao ,&nbsp;Daniel Pereira ,&nbsp;Cheryl F Rosen ,&nbsp;Richard J Cook ,&nbsp;Vinod Chandran ,&nbsp;Dafna D Gladman","doi":"10.1016/j.semarthrit.2025.152701","DOIUrl":"10.1016/j.semarthrit.2025.152701","url":null,"abstract":"<div><h3>Objectives</h3><div>Tuft resorption (TR) is an important radiographic feature of psoriatic arthritis (PsA). We aimed to define the prevalence of TR in patients with PsA, the clinical and radiographic features associated with it, and the risk factors for its occurrence.</div></div><div><h3>Methods</h3><div>We included patients with PsA followed at our prospective observational cohort. We defined TR as resorptive changes in the terminal tufts of the fingers or toes. We used generalized estimating equations to characterize clinical and radiographic features cross-sectionally associated with TR. We used multivariate Cox regression analysis to identify factors associated with the development of TR.</div></div><div><h3>Results</h3><div>Of the 1303 patients included in the study, 526 (40.4 %) were observed to have TR, of whom 181 (34.4 %) developed it during follow-up. TR was associated with older age (OR 1.49, <em>p</em> &lt; 0.01), longer duration of PsA (OR 1.03, <em>p</em> &lt; 0.01), higher radiographic damaged joint count (OR 1.02, <em>p</em> = 0.04), axial disease (OR 1.73, <em>p</em> &lt; 0.01), and the number of systemic disease-modifying anti-rheumatic drugs (DMARDs) used (OR 1.27, <em>p</em> &lt; 0.01). Male sex (HR 1.54, <em>p</em> = 0.01), vertebral osteopenia (HR 1.39, <em>p</em> = 0.02), and use of non-steroidal anti-inflammatory drugs (HR 1.43, <em>p</em> = 0.03) were associated with the development of TR. Use of biologic and targeted synthetic DMARDs was protective (HR 0.70, <em>p</em> = 0.05), although not significant at the 5 % level.</div></div><div><h3>Conclusion</h3><div>TR is a common radiographic feature of PsA. It is associated with more severe disease, including peripheral and axial radiographic damage.</div></div>","PeriodicalId":21715,"journal":{"name":"Seminars in arthritis and rheumatism","volume":"72 ","pages":"Article 152701"},"PeriodicalIF":4.6,"publicationDate":"2025-03-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143593153","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Molecular mechanisms underlying thrombosis in systemic lupus erythematosus – A Systematic review","authors":"Mads L Larsen ,&nbsp;Laura Nørgaard ,&nbsp;Petrus Linge ,&nbsp;Julie B Larsen ,&nbsp;Henrik Z Langkilde ,&nbsp;Ellen M Hauge ,&nbsp;Steffen Thiel ,&nbsp;Anne Voss ,&nbsp;Anders Bengtsson ,&nbsp;Anne Troldborg","doi":"10.1016/j.semarthrit.2025.152707","DOIUrl":"10.1016/j.semarthrit.2025.152707","url":null,"abstract":"<div><div>Patients with systemic lupus erythematosus (SLE) face an approximately 30 % risk of thrombosis post-diagnosis. However, there remains significant knowledge gaps regarding causative mechanisms, and there is a lack of specific antithrombotic guidelines.</div><div>This systematic review aims to examine the existing literature regarding the mechanisms contributing to thrombosis risk in SLE, focusing on five predefined procoagulant domains: autoantibodies (including antiphospholipid antibodies (aPL)), the complement system, platelets, the endothelium, and the coagulation system. The review followed the Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) statements and searched in PubMed and Embase without time restrictions. Risk of bias assessment was performed using a pre-specified evaluation tool.</div><div>Out of 3,747 initially identified publications, 30 studies were included, with 28 demonstrating robust methodological quality in the risk of bias assessment. The studies were experimental, involving blood samples from cross-sectional SLE cohorts, except one animal -and one case-control study. We identified six different thrombosis mechanisms of action. Most studies concentrated on autoantibodies, predominantly aPL. Shared mechanisms between aPL and other autoantibodies may account for the increased thrombosis risk in aPL-negative SLE patients. Significant knowledge gaps remain, particularly regarding the role of the complement system in SLE-related thrombosis. Also, most research relies on cross-sectional designs, emphasizing the need for prospective cohort studies to better assess clinical factors. Finally, comprehensive studies examining the interactions between multiple procoagulant factors and their link to thrombosis are lacking. Closing these gaps in future research could improve both preventive and personalized treatment strategies for thrombosis in SLE.</div></div>","PeriodicalId":21715,"journal":{"name":"Seminars in arthritis and rheumatism","volume":"72 ","pages":"Article 152707"},"PeriodicalIF":4.6,"publicationDate":"2025-03-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143620111","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}